Vancouver, British Columbia — Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful testing of a second-generation anti-cancer vaccine, called ARM-002TM, using its lead anti-cancer molecule AccuTOX®. When tested as a therapeutic vaccine in...
Latest News
SINGAPORE – In a breakthrough study published in the highly respected journal Cancer Cell, researchers have decoded critical genetic factors in intestinal metaplasia patients, shedding light on early signs and prevention strategies for stomach cancer – often a “ticking time bomb” as patients experience no or only mild symptoms in...
NEW YORK — Delcath Systems, Inc. (NASDAQ: DCTH) , a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that the United States Food and Drug Administration (“FDA”) granted Delcath’s application for orphan-drug designation for the drug melphalan for the treatment...
When America Alcantara of Austin quit ducking behind her mother and burying her face in her pudgy hands, she gleefully snapped photographs of the adults she had met an hour earlier in a medical office and spun in every empty chair on Monday. The energetic 7-year-old will slow down for...
Los Angeles, CA – As Parkinson’s disease diagnoses continue to rise in the U.S., limited patient access to movement disorder specialists means the job of delivering the often-devastating, lifechanging news falls on primary care physicians or community neurologists who may not have the necessary expertise for this sensitive task. A...
TOKUSHIMA, Japan — As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a Phase II clinical trial, has demonstrated fascinating longer median progression-free survival...
SOUTH SAN FRANCISCO, Calif. — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its BBB-crossing enzyme replacement...
DAKAR, Senegal — World-famous singer Youssou Ndour has a voice that is recognized across the globe. Now he’s using that voice to amplify the fight against malaria in his home country of Senegal with a new song “Xeex Sibbiru” (“Fight Malaria” in Wolof) and a multi-year partnership with Malaria No...
ST. PAUL, Minn. – People with memory problems who are depressed are more likely to develop Alzheimer’s disease compared to people who are not depressed, according to a study published in the June 16, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. However, the...
MINNEAPOLIS – In some diseases, the underlying processes can start years before a diagnosis is made. A new study finds that people who later develop multiple sclerosis (MS) are more likely to have conditions like depression, constipation and urinary tract infections five years before their MS diagnosis than people who...